Stock Track | Biocryst Pharmaceuticals Soars 5.06% Intraday on Positive Analyst Rating

Stock Track02-27

Biocryst Pharmaceuticals' stock surged 5.06% during intraday trading on Friday, following a positive analyst report from RBC Capital.

Brian Abrahams from RBC Capital maintained a Buy rating on BioCryst with a price target of $13.00, according to a report released prior to the market open. The analyst's continued bullish stance appears to have boosted investor confidence in the pharmaceutical company.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment